Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
Journal
Liver cancer
Journal Volume
8
Journal Issue
3
Pages
155-171
Date Issued
2019-05
Author(s)
Lin, Yu-Yang
Lin, Yin-Yao
Chen, Chia-Wei
Yu, Jhang-Sian
Abstract
Anti-programmed cell death-1(anti-PD1) treatment has shown promising antitumor efficacy in patients with advanced hepatocellular carcinoma (HCC). This study sought to explore the functional significance of programmed death ligand-1 (PD-L1) expression in tumor cells in the tumor microenvironment.
Subjects
Anti-programmed cell death-1; CD8+ T cells; Immune checkpoint inhibitor; Sorafenib; Tumor-infiltrating lymphocytes
SDGs
Other Subjects
antineoplastic agent; programmed death 1 ligand 1; rmp 114; sorafenib; unclassified drug; animal cell; animal experiment; animal model; Article; cancer immunotherapy; cancer transplantation; cell growth; cell proliferation; colony formation; controlled study; echography; flow cytometry; human; human cell; in vitro study; liver cancer cell line; liver cell carcinoma; liver transplantation; lymphocyte function; mouse; nonhuman; priority journal; protein expression; tumor microenvironment
Publisher
KARGER
Type
journal article